# Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

> **NCT00676845** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company** · enrollment: 133 (actual)

## Conditions studied

- Metabolic Syndrome
- Hypertension

## Interventions

- **DRUG:** olmesartan medoxomil
- **DRUG:** placebo
- **DRUG:** olmesartan medoxomil
- **DRUG:** olmesartan medoxomil

## Key facts

- **NCT ID:** NCT00676845
- **Lead sponsor:** Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00676845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00676845, "Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00676845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*